Skip to main content

Table 1 IMP3 related to clinico-pathological parameters of prostate cancer

From: Insulin-like growth factor II mRNA binding protein 3 (IMP3) is overexpressed in prostate cancer and correlates with higher Gleason scores

Variable Patients (n) Number of patients (IMP-Expression) (%)     p-Value (linear by linear)
   0 1 2 3  
pT-status       0.5
pT2 213 46 (21.6%) 131 (61.5%) 34 (16%) 2 (0.9%)  
pT3&4 212 25 (11.8%) 163 (76.9%) 23 (10.8%) 1 (0.5%)  
Gleason score       0.048
5-6 129 29 (22.5%) 85 (65.9%) 14 (10.9%) 1 (0.8%)  
7 182 28 (15.4%) 127 (69.8%) 26 (14.3%) 1 (0.5%)  
8-9 114 14 (12.3%) 82 (71.9%) 17 (14.9%) 1 (0.9%)  
Margin status       0.115
R0 262 54 (20.6%) 171 (65.3%) 34 (13%) 3 (1.1%)  
R1 163 17 (10.4%) 123 (75.5%) 23 (14.1%) 0 (0%)  
PSA (pre-OP)       0.21
< 10 ng/ml 192 37 (19.3%) 130 (67.7%) 24 (12.5%) 1 (0.5%)  
≥10 ng/ml 233 34 (14.6%) 164 (70.4%) 33 (14.2%) 2 (0.9%)  
Age       0.693
≤64 y 230 33 (14.3%) 168 (73%) 27 (11.7%) 2 (0.9%)  
> 64 y 195 38 (19.5%) 126 (64.6%) 30 (15.4%) 1 (0.5%)  
  1. Distribution of IMP3 expression in primary prostate cancer according to clinico-pathological parameters